Marshall Wace LLP Purchases 264,141 Shares of ALSP Orchid Acquisition Co. I (NASDAQ:ALOR)

Marshall Wace LLP boosted its stake in shares of ALSP Orchid Acquisition Co. I (NASDAQ:ALOR – Get Rating) by 96.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 537,206 shares of the company’s stock after acquiring an additional 264,141 shares during the quarter. Marshall Wace LLP owned approximately 2.39% of ALSP Orchid Acquisition Co. I worth $5,389,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Taconic Capital Advisors LP grew its holdings in ALSP Orchid Acquisition Co. I by 44.3% during the 3rd quarter. Taconic Capital Advisors LP now owns 488,335 shares of the company’s stock worth $4,898,000 after acquiring an additional 150,000 shares during the last quarter. Whitebox Advisors LLC bought a new stake in ALSP Orchid Acquisition Co. I during the 3rd quarter worth about $100,000. Verition Fund Management LLC grew its holdings in ALSP Orchid Acquisition Co. I by 17.4% during the 3rd quarter. Verition Fund Management LLC now owns 137,833 shares of the company’s stock worth $1,382,000 after acquiring an additional 20,433 shares during the last quarter. Elequin Capital LP bought a new stake in ALSP Orchid Acquisition Co. I during the 3rd quarter worth about $37,000. Finally, Bank of Montreal Can bought a new stake in ALSP Orchid Acquisition Co. I during the 3rd quarter worth about $1,319,000. Institutional investors own 62.09% of the company’s stock.

ALSP Orchid Acquisition Co. I Price Performance

Shares of NASDAQ:ALOR opened at $10.35 on Monday. ALSP Orchid Acquisition Co. I has a 12 month low of $9.90 and a 12 month high of $11.57. The company’s 50-day moving average price is $10.32 and its two-hundred day moving average price is $10.19.

ALSP Orchid Acquisition Co. I Company Profile

(Get Rating)

ALSP Orchid Acquisition Corporation I does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target life science companies in North America and Singapore.